European Medicines Agency recommends a variation to the terms of the marketing authorisation for two HPV vaccines

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal products Gardasil and Silgard. The CHMP adopted extension of indication to prevention of premalignant anal lesions and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. Read more here.